Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: A novel vaccine for renal cell carcinoma

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 133-140

  Zhang, Yao ^a   Luo, Chun L I ^a   He, Bai Cheng ^a   Zhang, Jia Mo ^a   Cheng, Gang ^a   Wu, Xiao Hou ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Exosomes; Immunotherapy; Interleukin 12; Renal cell carcinoma; Tumor vaccine

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; CARBONATE DEHYDRATASE IX; GAMMA INTERFERON; GLYCOLIPID; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HEAT SHOCK PROTEIN 70; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P35; INTERLEUKIN 12P40; PLASMID VECTOR; TUMOR REJECTION ANTIGEN; TUMOR VACCINE;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL BASED GENE THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; EXOSOME; FUSION GENE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY CELL; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECOMBINANT PLASMID; T LYMPHOCYTE; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; EXOSOMES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; KIDNEY NEOPLASMS; LEUKOCYTES, MONONUCLEAR; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 74549132676     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000484     Document Type: Article

References (35)

1. Mathew A, Devesa S, Fraumeni JF and Chow WH: Global increases in kidney cancer incidence: 1973-1992. Eur J Cancer Prev 11: 171-178, 2002.
2. Glaspy JA: Therapeutic options in the management of renal cell carcinoma. Semin Oncol 29: 41-46, 2002.
3. Wierecky J, Müller MR, Wirths S, et al: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66: 5910-5918, 2006.
4. Atzpodien J, Kirchner H, Jonas U, et al: Interleukin-2 and interferon-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma. Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22: 1188-1194, 2004.
5. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ and Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183: 1161-1172, 1996.
6. Andre F, Schartz NE, Movassagh M, et al: Malignant effusions and immunogenic tumor-derived exosomes. Lancet 360: 295-305, 2002.
7. Chaput N, Taïeb J, Schartz NE, André F, Angevin E and Zitvogel L: Exosome-based immunotherapy. Cancer Immunol Immunother 53: 234-239, 2004.
8. Wolfers J, Lozier A, Raposo G, et al: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL crosspriming. Nat Med 7: 297-303, 2001.
9. Théry C, Zitvogel L and Amigorena S: Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569-579, 2002.
10. Dai S, Wan T, Wang B, et al: More efficient induction of HLAA* 0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res 11: 7554-7563, 2005.
11. Zhang HG, Kim H, Liu C, et al: Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim Biophys Act 1773: 1116-1123, 2007.
12. Taylor DD and Gerçel TC: Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 92: 305-311, 2005.
13. Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84: 4008-4027, 1994.
14. Lesinski GB, Badgwell B, Zimmerer J, Crespin T, Hu Y, Abood G and Carson WE: IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. J Immunol 172: 7368-7376, 2004.
15. Colombo MP and Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168, 2002.
16. Sangro B, Melero I, Qian C, et al: Gene therapy of cancer based on interleukin 12. Curr Gene Ther 5: 573-581, 2005.
17. Nagarajan S and Selvaraj P: Glycolipid-anchored IL-12 expressed on tumor cell surface induced antitumor immune response. Cancer Res 62: 2869-2874, 2002.
18. Ji J, Li J, Holmes LM, Burgin KE, Yu X, Wagner TE and Wei Y: Glycoinositol phospholipid-anchored interleukin 2 but not secreted interleukin 2 inhibits melanoma tumor growth in mice. Mol Cancer Ther 1: 1019-1024, 2001.
19. Shuch B, Li Z and Belldegrun AS: Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. BJU Int 101: 25-30, 2008.
20. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C and Le Pecq JB: Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 270: 211-226, 2002.
21. Zitvogel L, Regnault A, Lozier A, et al: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4: 594-600, 1998.
22. Wang YC, Zhu L, McHugh R, et al: Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD80) costimulation. J Immunother 19: 1-8, 1996.
23. Lyons AB and Parish CR: Determination of lymphocyte division by flow cytometry. J Immunol Methods 171: 131-137, 1994.
24. Markel G, Seidman R, Cohen Y, et al: Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 126: 186-200, 2008.
25. Hao S, Moyana T and Xiang J: Cancer immunotherapy by exosome-based vaccines. Cancer Biother Radiopharmaceut 22: 692-703, 2007.
26. Kommu S: Renal-cell carcinoma: vaccination and risk of tumour progression. Lancet 363: 1557, 2004.
27. Belldegrun A, Muul LM and Rosenberg SA: Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48: 206-214, 1988.
28. Thurnher M, Radmayr C, Ramoner R, et al: Human renal cell carcinoma tissue contains dendritic cells. Int J Cancer 68: 1-7, 1996.
29. Yang Y, Xiu F, Cai Z, Wang J, Wang Q, Fu Y and Cao X: Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol 133: 389-399, 2007.
30. Clayton A, Mitchell JP, Court J, Mason MD and Tabi Z: Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 57: 7458-7466, 2007.
31. Smyth MJ, Taniguchi M and Street SE: The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165: 2665-70, 2000.
32. Gee MS, Koch CJ, Evans SM, et al: Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 59: 4882-4889, 1999.
33. Fujiwara H and Hamaoka T: Coordination of chemokine and adhesion systems in intratumoral T cell migration responsible for the induction of tumor regression. Int Immunopharmacol 1: 613-623, 2001.
34. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA and Multhoff G: Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 65: 5238-5247, 2005.
35. Segura E, Nicco C, Lombard B, et al: AM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106: 216-223, 2005.